1 min read
Add as a preferred source on Google

Sandoz Narrows 2026 Sales Guidance and Raises Margin Outlook

The company cited temporary challenges in Germany and short-term biosimilar supply constraints. Its SIX-listed shares closed down 2.70% at CHF 79.88 on Oct. 28.

A clear vial moves along a sterile pharmaceutical production line / TokenPost.ai
A clear vial moves along a sterile pharmaceutical production line / TokenPost.ai

Sandoz Group AG narrowed its 2026 net-sales growth guidance to 5%-6% at constant currencies and raised its core EBITDA margin guidance to 23.0%-23.5% in a Q3 and nine-month sales update released Wednesday, Oct. 28.

The company cited more challenging temporary market conditions in Germany and short-term biosimilar supply constraints in Europe and International as factors behind the guidance update.

SIX-listed shares (SDZ) closed down 2.70% at CHF 79.88 on Wednesday.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…